drug_type
RELEVANT_DRUG
intervention_type
Antibody-Drug Conjugate
drug_description
Bispecific antibody-drug conjugate targeting EGFR and HER3; after internalization, releases a topoisomerase I inhibitor payload (brengitecan) to induce DNA damage and tumor cell death.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Bispecific ADC that binds EGFR and HER3 on tumor cells, is internalized, and releases the topoisomerase I inhibitor payload brengitecan to induce DNA damage and tumor cell death.
drug_name
BL-B01D1 (izalontamab brengitecan; BMS-986507)
nct_id_drug_ref
NCT06437522